Another study analyzed claims data from the US to estimate the effect of alectinib on preventing BM in patients with ALK-positive NSCLC and found that ALK-positive NSCLC patients with BM accounted for approximately 1.32-fold higher PPPM costs than patients without BM [20]. This evidence concerns the gene ALK and non-small cell lung carcinoma.